Skip to content

Inspection Record

CellTrans Islet Isolation facility — FDA 483 Findings

US FDAInspected 2021-06-11Published 2026-10-30 11 findingsDeviation, CAPA, and investigationOther quality systemQuality unit oversightEquipment and facilityAseptic processing and sterility assuranceCleaning validationDocumentation and records

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

The current deviation reporting procedure was found deficient, for example: * During review of the(b) (4) system for monitoring of(6) 4) temperature and humidity, it was found that temperature excursions are not properly documented and reported as deviations.

2Other quality system

Your gowning procedures are deficient.

3Quality unit oversight

The Quality Unit oversight of(b) (4) is deficient.

4Equipment and facility

Effectiveness ofthe(b) (4) used for facility and?) caning was not demonstrated.

5Aseptic processing and sterility assurance

Regarding your firm's current aseptic process observed during inspection we noted the following deficiencies: * Sterile equipment was exposed to Iso(B)(4) before transferring into the (BD) (4) (b) (4) sok for use in your firm’s aseptic process.

6Other quality system

Your firm has not assessed for impurities regarding single(b)(4) parts cs.(b)(4) and sterilize hat are used in manufacturing ofthe product.

7Cleaning validation

CellTrans does not require periodic verification of(B) A)cleaning used w(D) (4) No such verification has been performed since 2018 when the initial cleaning validation was completed.

8Documentation and records

Final product lots were released with incomplete batch record or failed lot release specifications.

10Quality unit oversight

Your firm’s Quality Unit lacks a procedure/policy that details requirements for the following: An\ is used for receipt of, for example, deliveries ofyour firm’s r here is no procedure or policy in place that addresses the potential for deliveries that may be ) (4) or where possible storage in(b) (4) | may occur.

11Other quality system

Carbon dioxide gas used in incubator is not routinely monitored for chemical quality, oil, or particulate levels and no COA is available to describe gas quality.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

CellTrans Islet Isolation facility company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.